© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Scott T. Tagawa, MD, FACP, reviews the use of 177Lu-PSMA-617 radioligand therapy and clinical implications from the phases 3 VISION trial for patients with metastatic castration-resistant prostate cancer (mCRPC).
October 19th 2021
Scott T. Tagawa, MD, FACP, discusses the heterogeneity and features of prostate cancer and provides insight on biomarker testing.
Dr Scott T. Tagawa reviews traditional imaging techniques and advances in imaging used in clinical practice for prostate cancer.
An expert in prostate cancer reviews available options for the treatment of mCRPC and considerations for selecting the optimal therapy.
Scott T. Tagawa, MD, FACP, reviews the phase 3 VISION trial evaluating the use of 177Lu-PSMA-617 therapy in patients with mCRPC.
A prostate cancer expert considers clinical implications from the phase 3 VISION study, including the potential role of 177Lu-PSMA-617 therapy for patients with mCRPC.
Dr Scott T. Tagawa discusses common adverse events associated with 177Lu-PSMA-617 in patients with mCRPC and how to appropriately manage them.
Scott T. Tagawa, MD, FACP, shares his thoughts on remaining questions for imaging and PSMA-targeted therapy for mCRPC.
An expert in prostate cancer comments on emerging agents and combinations in the pipeline for the treatment of mCRPC.
Scott T. Tagawa, MD, FACP, shares clinical pearls and advice for the management of mCRPC.